HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect.

Abstract
Aberrant expression of Forkhead box (FOX) transcription factors plays vital roles in carcinogenesis. However, the function of the FOX family member FOXC1 in maintenance of colorectal cancer (CRC) malignancy is unknown. Herein, FOXC1 expression in CRC specimens in The Cancer Genome Atlas (TCGA) cohort was analyzed and validated using immunohistochemistry with a tissue microarray. The effect of FOXC1 expression on proliferation of and glycolysis in CRC cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. Our results showed that FOXC1 expression was higher in CRC specimens than in adjacent benign tissue specimens. Univariate survival analyses of the patients from whom the study specimens were obtained, and validated cohorts indicated that ectopic FOXC1 expression was significantly correlated with shortened survival. Silencing FOXC1 expression in CRC cells inhibited their proliferation and colony formation and decreased their glucose consumption and lactate production. In contrast, FOXC1 overexpression had the opposite effect. Furthermore, increased expression of FOXC1 downregulated that of a key glycolytic enzyme, fructose-1,6-bisphosphatase 1 (FBP1). Mechanistically, FOXC1 bound directly to the promoter regions of the FBP1 gene and negatively regulated its transcriptional activity. Collectively, aberrant FBP1 expression contributed to CRC tumorigenicity, and decreased FBP1 expression coupled with increased FOXC1 expression provided better prognostic information than did FOXC1 expression alone. Therefore, the FOXC1/FBP1 axis induces CRC cell proliferation, reprograms metabolism in CRCs, and constitutes potential prognostic predictors and therapeutic targets for CRC.
AuthorsQingguo Li, Ping Wei, Jitao Wu, Meng Zhang, Guichao Li, Yaqi Li, Ye Xu, Xinxiang Li, Dacheng Xie, Sanjun Cai, Keping Xie, Dawei Li
JournalOncogene (Oncogene) Vol. 38 Issue 4 Pg. 483-496 (01 2019) ISSN: 1476-5594 [Electronic] England
PMID30171256 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • FOXC1 protein, human
  • Forkhead Transcription Factors
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • RNA, Small Interfering
  • Recombinant Fusion Proteins
  • FBP1 protein, human
  • Fructose-Bisphosphatase
Topics
  • Adenocarcinoma (metabolism)
  • Animals
  • Apoptosis
  • Cell Cycle
  • Cohort Studies
  • Colorectal Neoplasms (metabolism)
  • Databases, Genetic
  • Disease-Free Survival
  • Forkhead Transcription Factors (antagonists & inhibitors, genetics, physiology)
  • Fructose-Bisphosphatase (antagonists & inhibitors, genetics, physiology)
  • Heterografts
  • Humans
  • Kaplan-Meier Estimate
  • Mice
  • Mice, Nude
  • Neoplasm Proteins (antagonists & inhibitors, genetics, physiology)
  • Promoter Regions, Genetic
  • RNA Interference
  • RNA, Messenger (biosynthesis)
  • RNA, Neoplasm (biosynthesis)
  • RNA, Small Interfering (genetics)
  • Recombinant Fusion Proteins (metabolism)
  • Signal Transduction (physiology)
  • Transcription, Genetic
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: